# Intelligent Bio Solutions Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Intelligent Bio Solutions Inc).

## Overview

Intelligent Bio Solutions Inc. develops and sells the Intelligent Fingerprinting Platform, a non-invasive drug screening system that uses fingerprint sweat, disposable cartridges, and a handheld reader to detect drugs of abuse. The company is commercializing this platform in markets outside the United States and is expanding through distributors and strategic partnerships across the UK, Europe, and APAC.

## Products & services

• Intelligent Fingerprinting Drug Screening System (IFP System)
• Fingerprint sweat test cartridges
• Portable handheld readers
• Confirmatory testing kits via third-party labs
• Accessories and other consumables
• Regulatory and market expansion support for new territories

- **Cartridges** (58%) — Disposable fingerprint sweat cartridges used for drug screening and recurring consumable revenue.
- **Readers** (27%) — Portable handheld analysis units that read cartridge results and enable the screening workflow.
- **Accessories and other sales** (15%) — Ancillary products and accessories sold alongside the core screening system.

- Intelligent Fingerprinting Drug Screening System (IFP System)
- Fingerprint sweat test cartridges
- Portable handheld readers
- Confirmatory testing kits through third-party labs
- Accessories and other consumables
- Market expansion and distribution enablement

## Customers

Customers are safety-critical organizations that need rapid, non-invasive drug screening for workforce, compliance, or treatment purposes. The company also serves judicial and rehabilitation-related users that need portable testing with fast turnaround and lower sample-handling burden than traditional methods.

- **Safety-critical employers** (primary) — Construction, transportation, logistics, manufacturing, and engineering customers buy the system to screen workers quickly and non-invasively.
- **Drug treatment and rehabilitation providers** (secondary) — Treatment organizations use the platform for rapid screening in rehabilitation settings where ease of use and patient acceptance matter.
- **Judicial and public-sector users** (secondary) — Courts and related organizations buy portable testing tools for enforcement and monitoring use cases.
- **Distribution partners** (primary) — Local distributors and diagnostic partners buy and resell the platform in their territories to expand market reach.

- Construction firms needing onsite drug screening for safety compliance
- Transportation and logistics operators managing workforce risk
- Manufacturing and engineering employers with safety-critical roles
- Drug treatment and rehabilitation organizations
- Judicial and public-sector users requiring portable screening
- Distributors that resell into local testing markets

## Geography

The company is headquartered in New York but operates through subsidiaries in Delaware, Australia, and the UK, reflecting a cross-border commercialization model. Management is prioritizing growth in the United Kingdom and mainland Europe while building sales and regulatory infrastructure for Australia, New Zealand, and broader APAC markets. Recent disclosures also show active expansion into Spain, Andorra, and other European and Middle Eastern markets through partners.

- **United Kingdom and mainland Europe** (55%) — Core commercialization focus based on management disclosures and partner expansion.
- **APAC** (20%) — Growth region targeted for new sales and distribution.
- **North America** (15%) — Corporate headquarters and product development base; limited commercial penetration disclosed.
- **Middle East and other international** (10%) — Emerging international markets referenced in product upgrade and partnership disclosures.

- Headquartered in New York, with operating subsidiaries in the US, UK, and Australia
- Commercial activity is concentrated outside the United States
- Priority markets include the United Kingdom and mainland Europe
- APAC expansion requires local regulatory approvals and distribution buildout
- Recent partner-led expansion includes Spain, Andorra, and the Middle East

## Strategy

The company is focused on shifting revenue toward higher-margin cartridges while maintaining the installed base of readers that enables recurring consumable sales. It is also expanding geographic reach through distributors and partnerships, while investing in regulatory approvals, product upgrades, and intellectual property to support broader commercialization.

- **Grow cartridge-led recurring revenue** (short-term) — Cartridges carry materially higher contribution margin than readers and support repeat purchases.
- **Expand European distribution** (medium-term) — Europe is the company’s most developed commercial region and a key source of near-term growth.
- **Enter APAC markets** (medium-term) — Australia, New Zealand, and broader APAC offer additional addressable markets but require regulatory readiness.
- **Strengthen product and IP position** (medium-term) — Product upgrades and patents help support adoption, localization, and competitive differentiation.

- Increase cartridge mix to improve gross margin and recurring revenue
- Expand market share in the UK and mainland Europe
- Build APAC sales and regulatory infrastructure
- Use distributor partnerships to accelerate local market access
- Upgrade the platform for multilingual and multi-region use
- Protect the cartridge technology with patents and IP

## Risks

The business remains exposed to customer concentration, supplier concentration, and execution risk as it scales a specialized medical technology platform. It also faces regulatory, funding, and listing-related risks typical of early commercial medtech companies, including dependence on approvals, government support, and continued access to capital.

- **Customer concentration** [high] — A small number of customers can materially affect revenue if orders slow or are lost.
- **Supplier concentration** [high] — The company relies on a limited supplier base for direct materials used in cartridges and readers.
- **Regulatory approval risk** [high] — Commercial expansion depends on satisfying local medical and screening regulations.
- **Financing and going-concern pressure** [high] — The company is loss-making and relies on external funding and support to continue scaling.
- **Nasdaq listing compliance** [medium] — Failure to meet continued listing requirements could impair liquidity and fundraising.

- Revenue concentration: one customer represented 21.6% of quarterly revenue
- Supplier concentration can disrupt cartridge and reader supply
- Regulatory approvals are needed for market expansion and product rollout
- Nasdaq listing compliance and financing access remain important risks
- Dependence on government support and R&D tax refunds affects liquidity
- Foreign exchange and international execution risk are material

## Accounting

Revenue is recognized on sales of cartridges, readers, and accessories, so product mix and shipment timing can materially change quarterly results. Investors should also watch government support income, deferred grant income, R&D tax refunds, lease liabilities, and foreign currency translation effects, all of which can move reported earnings and balance sheet strength.

- **Revenue recognition by product type** — Quarterly revenue and gross margin can swing with product mix.
- **Government support income and R&D tax refunds** — Can significantly reduce net loss in periods when recognized.
- **Deferred grant income** — Affects current liabilities and future other income.
- **Foreign currency translation** — Can create gains or losses in other comprehensive income and earnings.
- **Going concern and liquidity judgments** — Affects disclosure, valuation assumptions, and investor perception.

- Revenue mix between cartridges and readers affects gross margin
- Government support income and R&D tax refunds can offset losses
- Deferred grant income affects liability recognition and future income
- Foreign currency translation impacts reported results from overseas ops
- Lease liabilities and notes payable affect leverage and liquidity
- Internal control remediation may affect reporting reliability

---

*Last updated: 2026-09-24T10:46:57.885966+00:00*